Product Description
A novel TRPM8 agonist, to treat signs and symptoms of dry eye diseases. The novel mechanism of TRPM8 activation and an innovative delivery route of administration through eyelid wipe to treat both signs and symptoms of dry eye diseases will provide potentially a very differentiated product for dry eye treatment worldwide. We are on track to initiate the Phase I/II trial to dose dry eye patients directly in the first-in-human (FIH) clinical trials in Q2 2024. (Sourced from: https://www.iviewtherapeutics.com/news/iView-Therapeutics-Inc.-Announced-FDA%E2%80%99s-Clearance-of-IND-Application-for-IVW-1001-Ophthalmic-Eyelid-Wipe-to-Treat-Signs-and-Symptoms-of-Dry-Eye-Disease)
Mechanisms of Action: TRPM8 Agonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IVIEW Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IVW-1001-CS-101 | P2 |
Recruiting |
Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2025-07-01 |